His primary areas of study are Internal medicine, Endocrinology, Diabetes mellitus, Insulin and Type 2 diabetes. In his work, Exenatide and Randomized controlled trial is strongly intertwined with Liraglutide, which is a subfield of Internal medicine. His works in Glucagon-like peptide-1, Glucagon, Incretin, Postprandial and Insulin resistance are all subjects of inquiry into Endocrinology.
He has included themes like Gastrointestinal hormone and Glucagon secretion in his Glucagon-like peptide-1 study. His work carried out in the field of Diabetes mellitus brings together such families of science as Gastroenterology and Carbohydrate metabolism. He combines subjects such as Basal, Glucose tolerance test, Glucose clamp technique and Skeletal muscle with his study of Type 2 diabetes.
Sten Madsbad focuses on Internal medicine, Endocrinology, Insulin, Diabetes mellitus and Type 2 diabetes. While the research belongs to areas of Internal medicine, he spends his time largely on the problem of Glucagon-like peptide-1, intersecting his research to questions surrounding Gastric emptying. Incretin, Pancreatic hormone, C-peptide, Carbohydrate metabolism and Liraglutide are among the areas of Endocrinology where the researcher is concentrating his efforts.
His study in Insulin is interdisciplinary in nature, drawing from both Hormone and Type 1 diabetes. His work in Diabetes mellitus addresses subjects such as Gastric bypass surgery, which are connected to disciplines such as Roux-en-Y anastomosis. His Type 2 diabetes research includes elements of Metformin, Body mass index, Surgery, Gastroenterology and Type 2 Diabetes Mellitus.
His primary scientific interests are in Internal medicine, Endocrinology, Diabetes mellitus, Type 2 diabetes and Insulin. His research in Internal medicine intersects with topics in Gastroenterology and Liraglutide. His work on Hormone, Carbohydrate metabolism and Glucagon-like peptide-1 as part of general Endocrinology study is frequently linked to Peptide YY, therefore connecting diverse disciplines of science.
His Diabetes mellitus research incorporates themes from Relative risk, Confidence interval and Gastric bypass surgery. In Type 2 diabetes, Sten Madsbad works on issues like Metformin, which are connected to Adverse effect. His Insulin study which covers Type 1 diabetes that intersects with Bolus.
His scientific interests lie mostly in Internal medicine, Endocrinology, Type 2 diabetes, Postprandial and Diabetes mellitus. His research integrates issues of Gastroenterology and Liraglutide in his study of Internal medicine. His study in the field of Glucagon, Insulin resistance, Small intestine and NEFA is also linked to topics like Context.
His work deals with themes such as Glucagon-like peptide-1, Appetite and Weight loss, which intersect with Postprandial. In his papers, Sten Madsbad integrates diverse fields, such as Diabetes mellitus and Crossover study. His Insulin research integrates issues from Type 1 diabetes and Carbohydrate.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study
Mette Zander;Mette Zander;Sten Madsbad;Jan Lysgaard Madsen;Jens Juul Holst.
The Lancet (2002)
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.
Mai-Britt Toft-Nielsen;Mette B. Damholt;Sten Madsbad;Linda M. Hilsted.
The Journal of Clinical Endocrinology and Metabolism (2001)
Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients
Tina Vilsbøll;Thure Krarup;Carolyn F. Deacon;Sten Madsbad.
Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
Anthony H. Barnett;Stephen C. Bain;Paul Bouter;Bengt Karlberg.
The New England Journal of Medicine (2004)
Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes
Tina Vilsbøll;Milan Zdravkovic;Tu Le-Thi;Thure Krarup.
Diabetes Care (2007)
The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion: Effects on β-Cell Sensitivity in Type 2 and Nondiabetic Subjects
Lise L. Kjems;Jens J. Holst;Aage Vølund;Sten Madsbad.
Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
Tina Vilsbøll;T Krarup;J Sonne;S Madsbad.
The Journal of Clinical Endocrinology and Metabolism (2003)
Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
Tina Vilsbøll;T Krarup;S Madsbad;Jens Møller Holst.
Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.
Sten Madsbad;Ole Schmitz;Jonas Ranstam;Grethe Jakobsen.
Diabetes Care (2004)
Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
Tina Vilsbøll;Thure Krarup;Sten Madsbad;Jens Juul Holst.
Regulatory Peptides (2003)
Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking h-index is inferred from publications deemed to belong to the considered discipline.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: